Skip to main content
All lobbying filings

GUIDEWELL MUTUAL HOLDING CORPORATION

Lobbying for GUIDEWELL MUTUAL HOLDING CORPORATION

 Filing 2nd Quarter - Report
2nd Quarter (Apr 1 - June 30) 2025 · Florida · House · Senate · $10,000.00 expenses · posted Jul 21, 2025

Official filing document

 Bills named in this filing 23
  • HR 1227
    Alternatives to PAIN Act
  • HR 2433
    Reducing Medically Unnecessary Delays in Care Act of 2025
  • S 1041
    Affordable Prescriptions for Patients Act
  • S 1040
    Drug Competition Enhancement Act
  • S 1096
    Preserve Access to Affordable Generics and Biosimilars Act
  • S 1095
    Stop STALLING Act
  • HR 7149
    EASE Act of 2024
  • S 4078
    EASE Act of 2024
  • HR 5746
    Addressing Whole Health in Medicare Advantage Act
  • HR 7623
    Telehealth Modernization Act of 2024
  • HR 7996
    Improving CARE for Youth Act
  • S 2556
    Improving CARE for Youth Act
  • S 1114
    Expanding Access to Low-Cost Generics Act of 2023
  • S 2305
    Biosimilar Red Tape Elimination Act
  • S 148
    Stop STALLING Act
  • S 1339
    Pharmacy Benefit Manager Reform Act
  • S 775
    Increasing Transparency in Generic Drug Applications Act
  • HR 3839
    To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
  • S 150
    Affordable Prescriptions for Patients Act of 2023
  • HR 9070
    Affordable Prescriptions for Patients Act of 2024
  • S 1542
    DRUG Act
  • S 142
    Preserve Access to Affordable Generics and Biosimilars Act
  • S 1067
    Ensuring Timely Access to Generics Act of 2023
 Lobbying activity 2
Medicare/Medicaid

Issues: Same-day billing restrictions in Medicaid; Medicare Advantage & MA Rate Notice; Medicare/Transparency; Medicaid Cuts; Mental Health Care, Youth Mental Health; Site neutral payment reform; Healthy Equity Index reward factor; Value Base Care Bills: H.R. 7149, Equal Access to Specialty Care Everywhere (EASE) Act of 2024 To amend title XI of the Social Security Act to require the Center for Medicare and Medicaid Innovation to test a model to improve access to specialty health services for certain Medicare and Medicaid beneficiaries. Sponsor: Rep. Steel, Michelle [R-CA-45] S.4078 - EASE Act of 2024 To amend title XI of the Social Security Act to require the Center for Medicare and Medicaid Innovation to test a model to improve access to specialty health services for certain Medicare and Medicaid beneficiaries. Sponsor: Sen. Mullin, Markwayne [R-OK] H.R.5746 - Addressing Whole Health in Medicare Advantage Act To amend title XVIII of the Social Security Act to expand the availability of supplemental benefits to certain Medicare Advantage enrollees. Sponsor: Rep. Bilirakis, Gus M. [R-FL-12] H.R. 7623, Telehealth Modernization Act To amend title XVIII of the Social Security Act to make permanent certain telehealth flexibilities under the Medicare program. Sponsor: Rep. Carter, Earl L. "Buddy" [R-GA-1] H.R. 7996, Improving CARE for Youth Act To amend title XIX of the Social Security Act to ensure Medicaid coverage of mental health services and primary care services furnished on the same day. Sponsor: Rep. Dunn, Neal P. [R-FL-2] S.2556 - Improving CARE for Youth Act To amend title XIX of the Social Security Act to ensure Medicaid coverage of mental health services and primary care services furnished on the same day. Sponsor: Sen. Carper, Thomas R. [D-DE] H.R.1227 - Alternatives to PAIN Act To amend title XVIII of the Social Security Act to ensure appropriate access to non-opioid pain management drugs under part D of the Medicare program. Sponsor: Rep. Miller-Meeks, Mariannette [R-IA-1] H.R.2433 - Reducing Medically Unnecessary Delays in Care Act of 2025 To ensure that prior authorization medical decisions under Medicare are determined by physicians. Sponsor: Rep. Green, Mark E. [R-TN-7]

Pharmacy

Issues: 340B Program/Transparency; generics access; Pharmacy Benefit Managers; Prescription Drug Cost; Step Therapy Bills: S. 1114, Expanding Access to Low-Cost Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. Sponsor: Sen. Smith, Tina [D-MN] S. 2305 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S. 148 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Amy Klobuchar (D-MN) S.1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. Sponsor: Sen. Sanders, Bernard [I-VT] S. 775, Increasing Transparency in Generic Drug Applications To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.3839 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] S. 150 - Affordable Prescriptions for Patients Act of 2023 To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] H.R.9070 - Affordable Prescriptions for Patients Act of 2024 To amend title 35, United States Code, to prohibit product hopping, and for other purposes. Sponsor: Rep. Issa, Darrell [R-CA-48] S.1542, DRUG Act To improve services provided by pharmacy benefit managers. Sponsor: Sen. Marshall, Roger [R-KS] S. 142 - Preserve Access to Affordable Generics and Biosimilars Act To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S. 1067, Ensuring Timely Access to Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN]

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem